Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FLT3 |
Variant | Y842D |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FLT3 Y842D lies within the protein kinase domain of the Flt3 protein (UniProt.org). Y842D has been demonstrated to occur as a secondary resistance mutation in the context of FLT3 internal tandem duplication (FLT3-ITD) mutations (PMID: 19318574, PMID: 25487917), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, May 2024). |
Associated Drug Resistance | Y |
Category Variants Paths |
FLT3 mutant FLT3 exon20 FLT3 Y842D |
Transcript | NM_004119.3 |
gDNA | chr13:g.28018484A>C |
cDNA | c.2524T>G |
Protein | p.Y842D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004119.2 | chr13:g.28018484A>C | c.2524T>G | p.Y842D | RefSeq | GRCh38/hg38 |
NM_004119.3 | chr13:g.28018484A>C | c.2524T>G | p.Y842D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 Y842D | acute myeloid leukemia | predicted - sensitive | Cytarabine + Idarubicin + Midostaurin | Case Reports/Case Series | Actionable | In a clinical case study, Rydapt (midostaurin), Cytosar-U (cytarabine), and Idamycin (idarubicin) combination therapy resulted in complete morphological remission, allowing for subsequent allogeneic stem cell transplantation, in a patient with acute myeloid leukemia harboring FLT3 Y842D (PMID: 35549749). | 35549749 |